Table 2.
Characteristics of the patient assessments
| N (%) | Range | Mean (SD) | |
|---|---|---|---|
| Total patient assessments | 770 (100.0) | ||
| Female patient | 445 (57.8) | ||
| Oral supplements taken | 254 (33.0) | ||
| Enteral tube feeds taken | 122 (15.8) | ||
| CFRD present | 287 (37.3) | ||
| TIVAD fitted | 402 (52.2) | ||
| Burkholderia cepacia complex present | 58 (7.5) | ||
| Listed for transplant | 35 (4.5) | ||
| Received transplant | 97 (12.6) | ||
| Ages (years) | 14–57 | 28.5 ( 8.2) | |
| FEV1% predicted | 12–133 | 58.3 (23.8) | |
| BMI | 15–34 | 21.8 ( 3.1) | |
| Physical functioning | 2–100 | 83.0 (20.5) | |
| Social functioning | 0–100 | 84.7 (21.5) | |
| Emotional responses | 8–100 | 78.6 (20.6) | |
| Treatment issues | 0–100 | 74.7 (22.5) | |
| Chest symptoms | 0–100 | 76.6 (23.2) | |
| Body image | 0–100 | 69.8 (24.7) | |
| Interpersonal relationships | 2–100 | 64.5 (22.4) | |
| Career concerns | 0–100 | 61.7 (29.4) | |
| Concerns for the future | 0–100 | 45.0 (25.1) |
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s, TIVAD, totally implantable vascular access device.